Baidu
map

BJC:II型糖尿病的绝经后妇女患乳腺癌风险增加

2012-09-19 网络 网络

这项研究是由里昂国际预防研究所(I-PRI)领导实施完成,研究人员归纳分析了40项独立的相关研究的研究结果,以期找出乳腺癌和糖尿病之间的潜在联系。这些研究涉及共超过56000例乳腺癌患者,患者遍布四大洲,结果发现II型糖尿病的绝经后妇女患乳腺癌的风险增加了27%。 患乳腺癌风险的增加似乎只在患有II型糖尿病的绝经后妇女人群中发现,本研究发现II型糖尿病绝经前妇女或I型糖尿病妇女患者发展罹患乳

这项研究是由里昂国际预防研究所(I-PRI)领导实施完成,研究人员归纳分析了40项独立的相关研究的研究结果,以期找出乳腺癌和糖尿病之间的潜在联系。这些研究涉及共超过56000例乳腺癌患者,患者遍布四大洲,结果发现II型糖尿病的绝经后妇女患乳腺癌的风险增加了27%。

患乳腺癌风险的增加似乎只在患有II型糖尿病的绝经后妇女人群中发现,本研究发现II型糖尿病绝经前妇女或I型糖尿病妇女患者发展罹患乳腺癌的风险较低。研究还表明,常与糖尿病发病有关的体重指数(BMI)也可能是诱发患者得乳腺癌的一个潜在因素。

这项研究的主要作者Peter Boyle教授说:我们的研究发现,糖尿病患者罹患乳腺癌的风险显著增加,但这仅限于绝经后妇女。并且我们尚未知道II型糖尿病增加患乳腺癌风险的背后机制。

肥胖增加绝经后妇女患乳腺癌的风险达30%,在英国每年4000多例乳腺癌发病与体重过重有关,英国癌症研究中心Martin Ledwick护士说:在这项研究中,虽然目前还不清楚糖尿病和绝经后妇女患乳腺癌风险之间是否有因果关系。但我们知道的是,高的体重指数会促进II型糖尿病和乳腺癌两种疾病的风险增加,因此,妇女保持健康的体重是有科学依据的。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061348, encodeId=478e20613486d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 17 20:15:00 CST 2012, time=2012-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770201, encodeId=52f91e7020128, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Dec 09 07:15:00 CST 2012, time=2012-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256972, encodeId=e4e112569e267, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331990, encodeId=e346133199032, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429661, encodeId=0722142966154, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631469, encodeId=6f611631469d7, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=)]
    2012-12-17 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061348, encodeId=478e20613486d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 17 20:15:00 CST 2012, time=2012-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770201, encodeId=52f91e7020128, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Dec 09 07:15:00 CST 2012, time=2012-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256972, encodeId=e4e112569e267, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331990, encodeId=e346133199032, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429661, encodeId=0722142966154, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631469, encodeId=6f611631469d7, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061348, encodeId=478e20613486d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 17 20:15:00 CST 2012, time=2012-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770201, encodeId=52f91e7020128, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Dec 09 07:15:00 CST 2012, time=2012-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256972, encodeId=e4e112569e267, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331990, encodeId=e346133199032, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429661, encodeId=0722142966154, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631469, encodeId=6f611631469d7, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061348, encodeId=478e20613486d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 17 20:15:00 CST 2012, time=2012-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770201, encodeId=52f91e7020128, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Dec 09 07:15:00 CST 2012, time=2012-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256972, encodeId=e4e112569e267, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331990, encodeId=e346133199032, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429661, encodeId=0722142966154, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631469, encodeId=6f611631469d7, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061348, encodeId=478e20613486d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 17 20:15:00 CST 2012, time=2012-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770201, encodeId=52f91e7020128, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Dec 09 07:15:00 CST 2012, time=2012-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256972, encodeId=e4e112569e267, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331990, encodeId=e346133199032, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429661, encodeId=0722142966154, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631469, encodeId=6f611631469d7, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2061348, encodeId=478e20613486d, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 17 20:15:00 CST 2012, time=2012-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770201, encodeId=52f91e7020128, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Dec 09 07:15:00 CST 2012, time=2012-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256972, encodeId=e4e112569e267, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331990, encodeId=e346133199032, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429661, encodeId=0722142966154, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631469, encodeId=6f611631469d7, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 21 02:15:00 CST 2012, time=2012-09-21, status=1, ipAttribution=)]
    2012-09-21 zxxiang

相关资讯

IJCP:临床试验表明II型糖尿病药物利拉利汀长期使用有效且安全

利拉利汀(linagliptin)通过阻断二肽基肽酶-4(DPP-4)活性而发挥作用,其中DPP-4一种破坏激素GLP-1的酶,而GLP-1则有助于当需要胰岛素时,身体产生更多的胰岛素。 对II型糖尿病患者开展的一项长期的药物临床试验证实一种口服DPP-4抑制剂利拉利汀是安全的和有效的,这就意味着利用利拉利汀或者与其他选定的口服抗糖尿病药物一起能够降低血糖水平长达102周。 由31个国家参与的

PLoS ONE:A2b型腺苷受体在调节肥胖和II型糖尿病中发挥着重要作用

来自美国波士顿大学医学院的一项研究证实A2b型腺苷受体(A2b-type adenosine receptor, A2bAR)在调节高脂肪和高胆固醇饮食诱导的II型糖尿病症状中发挥着非常重要的作用,而且还鉴定出A2bAR能够作为治疗II型糖尿病的潜在靶标。相关研究发现于2012年7月25日在线发表在PLoS ONE期刊上。 含有高脂肪和高胆固醇的饮食导致身体在调节血糖水平上发生变化。锻炼导致细胞

Blood:II型糖尿病患者更易患血癌?!

       近日,来自米利亚姆医院的研究者运用一种新的综合分析技术分析表明,II型糖尿病病人存在20%患血癌的风险,如非霍奇金淋巴瘤、白血病和骨髓瘤。这项研究刊登在了Blood杂志上,研究数据为糖尿病和特定类型的癌症之间的联系提供了证据。        研究者Jorge Castill

Baidu
map
Baidu
map
Baidu
map